Subtopic Deep Dive
Rituximab in Vasculitis
Research Guide
What is Rituximab in Vasculitis?
Rituximab in vasculitis refers to the use of the anti-CD20 monoclonal antibody for induction and maintenance therapy in ANCA-associated vasculitis through B-cell depletion.
Key RCTs like RAVE (Stone et al., 2010, 2665 citations) and RITUXVAS (Jones et al., 2010, 1704 citations) established rituximab as non-inferior to cyclophosphamide for remission induction. MAINRITSAN (Guillevin et al., 2014, 1049 citations) showed superiority over azathioprine for maintenance. Over 10 major trials and guidelines shape current standards.
Why It Matters
Rituximab provides steroid-sparing options in ANCA-associated vasculitis, reducing cyclophosphamide toxicity and relapse rates (Stone et al., 2010; Guillevin et al., 2014). EULAR recommendations (Yates et al., 2016) and ACR guidelines (Chung et al., 2021) endorse it for induction and maintenance, transforming care for granulomatosis with polyangiitis and microscopic polyangiitis. Real-world adoption lowers infection risks compared to prolonged steroids.
Key Research Challenges
Infection Risks Post-Depletion
Rituximab increases serious infection rates due to B-cell depletion, particularly in elderly patients (Specks et al., 2013). Balancing efficacy against immunosuppression remains critical. Long-term data on hypogammaglobulinemia is limited.
Optimal Dosing Schedules
Fixed-interval vs. PR3-ANCA driven retreatment strategies show varying relapse prevention (Guillevin et al., 2014). RAVE trial used single-course rituximab (Stone et al., 2010). Standardization lacks consensus.
Refractory Disease Response
Outcomes in relapsing or refractory cases vary, with superiority in relapsers noted in RAVE (Stone et al., 2010). Genetic subsets influence response (Lyons et al., 2012). Predictors of non-response need identification.
Essential Papers
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone, Peter A. Merkel, Robert Spiera et al. · 2010 · New England Journal of Medicine · 2.7K citations
Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the Natio...
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel Jones, Jan Willem Cohen Tervaert, Thomas Häuser et al. · 2010 · New England Journal of Medicine · 1.7K citations
A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-base...
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Max Yates, Richard A. Watts, Ingeborg M. Bajema et al. · 2016 · Annals of the Rheumatic Diseases · 1.2K citations
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loı̈c Guillevin, Christian Pagnoux, Alexandre Karras et al. · 2014 · New England Journal of Medicine · 1.0K citations
More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov nu...
Genetically Distinct Subsets within ANCA-Associated Vasculitis
Paul Lyons, Tim F. Rayner, Sapna Trivedi et al. · 2012 · New England Journal of Medicine · 997 citations
This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis tha...
EULAR recommendations for the management of primary small and medium vessel vasculitis
Chetan Mukhtyar, Loı̈c Guillevin, María C. Cid et al. · 2008 · Annals of the Rheumatic Diseases · 984 citations
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler, Praveen Akuthota, David Jayne et al. · 2017 · New England Journal of Medicine · 982 citations
In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did place...
Reading Guide
Foundational Papers
Read Stone et al. (2010, RAVE, 2665 citations) first for induction efficacy benchmark; Jones et al. (2010, RITUXVAS) for renal outcomes; Guillevin et al. (2014, MAINRITSAN) for maintenance superiority.
Recent Advances
Study Chung et al. (2021, ACR guidelines, 594 citations) for current standards; Jayne et al. (2021, avacopan comparison) contextualizes rituximab role.
Core Methods
B-cell depletion via 375mg/m2 rituximab x4 with steroids; endpoints include BVAS remission, ANCA titres; genetic subtyping via PR3/MPO (Lyons et al., 2012).
How PapersFlow Helps You Research Rituximab in Vasculitis
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Rituximab ANCA vasculitis' to map 10+ RCTs from Stone et al. (2010, 2665 citations) as central node, then findSimilarPapers reveals MAINTENANCE trials like Guillevin et al. (2014). exaSearch uncovers real-world cohorts beyond RCTs.
Analyze & Verify
Analysis Agent applies readPaperContent to extract remission rates from RAVE (Stone et al., 2010), verifies meta-analysis claims via verifyResponse (CoVe) against raw data, and uses runPythonAnalysis for GRADE grading of RCTs, computing odds ratios with pandas for infection risks (Specks et al., 2013). Statistical verification confirms non-inferiority (p<0.001).
Synthesize & Write
Synthesis Agent detects gaps in refractory vasculitis data via contradiction flagging between RITUXVAS (Jones et al., 2010) and real-world relapse rates; Writing Agent uses latexEditText for guideline summaries, latexSyncCitations to link EULAR (Yates et al., 2016), and latexCompile for trial comparison tables, with exportMermaid for RCT flowcharts.
Use Cases
"Run meta-analysis of rituximab infection rates vs cyclophosphamide in AAV RCTs"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on 5 RCTs like Stone 2010, Jones 2010) → outputs forest plot CSV and GRADE-assessed OR=1.2 (95% CI).
"Draft LaTeX review section on rituximab maintenance strategies citing MAINRITSAN"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Guillevin 2014) + latexCompile → researcher gets formatted PDF section with remission curves.
"Find code for ANCA vasculitis genetic analysis like Lyons 2012"
Research Agent → citationGraph (Lyons 2012) → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → outputs R scripts for PR3/MPO subset clustering.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ rituximab papers: searchPapers → citationGraph → readPaperContent → GRADE grading → structured report on induction efficacy. DeepScan applies 7-step CoVe chain to verify EULAR recommendations (Yates et al., 2016) against primary RCTs. Theorizer generates hypotheses on genetic predictors from Lyons et al. (2012) + Stone et al. (2010).
Frequently Asked Questions
What is the definition of rituximab in vasculitis?
Rituximab is an anti-CD20 monoclonal antibody used for B-cell depletion in induction and maintenance of ANCA-associated vasculitis (Stone et al., 2010).
What are key methods in rituximab vasculitis trials?
RCTs compare rituximab to cyclophosphamide (RAVE: 375mg/m2 x4, Stone et al., 2010) or azathioprine for maintenance (MAINRITSAN: 500mg x3 then every 6 months, Guillevin et al., 2014).
What are key papers on rituximab in vasculitis?
RAVE (Stone et al., 2010, 2665 citations) showed non-inferiority for induction; MAINRITSAN (Guillevin et al., 2014, 1049 citations) superior maintenance; RITUXVAS (Jones et al., 2010, 1704 citations) renal focus.
What are open problems in rituximab vasculitis research?
Optimal retreatment timing, infection risk mitigation, and response in genetic subsets (Lyons et al., 2012) remain unresolved; long-term safety data needed.
Research Vasculitis and related conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Rituximab in Vasculitis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vasculitis and related conditions Research Guide